English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 31 October 2019, 11:10 HKT/SGT
COPFL announced that its wholly-owned subsidiary-ZKO, has successfully completed a Phase II trial of Cyclosporine A Ophthalmic Gel

China, Oct 31, 2019 - (ACN Newswire) - China Ophthalmology Focus Limited ("COPFL") today announced that its wholly-owned subsidiary, Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Limited ("ZKO"), has successfully completed a Phase II trial of Cyclosporine A (CsA) Ophthalmic Gel in China (clinicaltrials.gov registration No.:NCT03676335). Topline data show that the experimental drug has similar or a trend towards better efficacy than that of the marketed CsA Ophthalmic Emulsion.

The recently completed trial is a Phase II, randomised, single-blind, positive controlled, dose-finding study to assess the safety and efficacy of CsA Ophthalmic Gel in subjects with dry eye (Keratoconjunctivitis Sicca). The objective of the study is to explore and compare the efficacy and safety of CsA in a proprietary ophthalmic gel formulation with CsA Emulsion (formulation currently available on western markets) in the treatment of the above indication using different dosages and frequencies of administration, and to preliminarily determine the optimal conditions for the design of follow-up clinical study.

A total of 240 patients were enrolled in this study from 13 centers in China. The experimental drugs were given to three separate groups of subjects as follows: Treatment group A: CsA ophthalmic gel: 0.3 g: 0.15 mg, once daily; Treatment group B: CsA ophthalmic gel: 0.3 g: 0.15 mg, twice daily, with an interval of 12 hours; Treatment group C: CsA ophthalmic gel: 0.3 g: 0.3 mg, once daily. The positive control group received CsA Emulsion: 0.4 ml: 0.2 mg, twice daily, with an interval of 12 hours.

"Topline data of the current trial showed the new CsA Ophthalmic Gel formulation, (0.3 g: 0.15 mg, once daily) has similar or a trend towards better efficacy than the emulsion formulation currently on the western market," said Dr. Lit-Fui Lau, President of ZKO. "We believe that CsA Ophthalmic Gel is well positioned to address the unmet medical need in the treatment of patients with dry eye in China where ophthalmic CsA is still unavailable." "We have spent 10 years in the development of the patent-protected proprietary ophthalmic gel formulation of CsA. The topline data validated our commitment to the development of this innovative product," said Dr. Benjamin Li, Executive Director of COPFL.

ZKO plans to meet with the Center for Drug Evaluation in China to discuss and agree upon a Phase III protocol of the CsA Ophthalmic Gel trial. The pivotal study is expected to initiate patient recruitment in early 2020.

About Cyclosporine A Ophthalmic Gel

Cyclosporine A is a natural cyclic polypeptide immunosuppressant. It acts as a calcineurin inhibitor and suppresses T lymphocytes from releasing pro-inflammatory cytokines. The Cyclosporine A Ophthalmic Gel is a proprietary product shown to possess superior pharmacokinetics profile than that of the emulsion formulation in preclinical studies. It is under development for the treatment of keratoconjunctivitis sicca (dry eye) in China.

About China Ophthalmology Focus Ltd.

COPFL is an indirect non-wholly owned subsidiary of Lee's Pharmaceutical Holdings Limited (HKEx: 0950). Its Series A fund raising of USD 50 million in June 2019 was contributed by reputable investors including Coyote Investment Pte. Ltd., Panacea Venture Healthcare Fund I, L.P., Smart Rocket Ltd. and Vertex Profit International Ltd.. COPFL specializes in the development, manufacturing and marketing of ophthalmic drugs. It has built up a state-of-the-art development and production facility in Nansha, Guangzhou through its 100% subsidiary Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Limited. The facility supports the in-house development and future commercialisation of over 21 proprietary products and difficult to manufacture generics (ranged from pre-clinical to registration stage) for the Chinese and ASEAN markets. Its portfolio is diversified in having both small molecules and biologics, and having both novel and generic medicines, covering different ophthalmic indications from dry eye syndrome, glaucoma, wet Age-related Macular Degeneration (AMD), diabetic retinopathy to corneal and inflammatory diseases. It is currently the only modern facility in China that is recognised as being designed and built for ophthalmic drugs according to all applicable standards, namely China, Pharmaceutical Inspection Co-operation Scheme (PIC/S), EMEA, Japan and Food and Drug Administration (FDA).

Topic: Press release summary Sectors: Daily Finance, Healthcare & Pharm
From the Asia Corporate News Network

Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Latest Press Releases
nybl Joins World AI Show & Awards as The Official Artificial Intelligence Partner  
Sunday, May 22, 2022 9:07:00 AM
Straumann Malaysia, part of The Straumann Group, a Leading Implantology Company, Intends to Provide 3,000 Dental Implant Packages to the Ministry of Health Malaysia as part of MoU  
May 21, 2022 08:20 HKT/SGT
MC and Morgenrot Enter into Capital and Business Alliance  
Friday, May 20, 2022 7:19:00 PM
12th PropertyGuru Asia Property Awards (Singapore) search for the finest real estate as market sentiment improves  
May 20, 2022 19:15 HKT/SGT
PhilSec 2022 Set to Discuss Strategies to Strengthen Philippines' Cybersecurity  
May 20, 2022 16:35 HKT/SGT
TMT Offers Immersive Customer Experience with Latest Megastore in Pavilion Bukit Jalil  
May 20, 2022 16:00 HKT/SGT
ROOKIE Racing and TOM'S SPIRIT Announce Team Setups for Super Taikyu Series Fuji 24 Hours Race  
Friday, May 20, 2022 12:42:00 PM
Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit  
May 20, 2022 11:10 HKT/SGT
MC and Kurashiki City Sign Regional Development Agreement  
Friday, May 20, 2022 9:55:00 AM
BDO announces winners of the BDO ESG Awards 2022  
Thursday, May 19, 2022 9:20:00 PM
More Press release >>
More events >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575